Experimental leukemia drug offered to patients before official approval
NCT ID NCT06439966
Summary
This program provided early access to an investigational drug called ABBV-787 for people with acute myeloid leukemia before it received full regulatory approval. It was designed for eligible patients who had no other suitable treatment options and could not join ongoing clinical trials. Doctors could request the drug for individual patients if they believed the potential benefits outweighed the risks based on the patient's specific medical situation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.